Ijaz M K, Nur-E-Kamal M S, Dar F K, Uduman S, Redmond M J, Attah-Poku S K, Dent D, Babiuk L A
Division of Infectious Diseases, H.H. Shaikh Khalifa Research Centre for Racing Camels, Abu-Dhabi, United Arab Emirates.
Vaccine. 1998 May-Jun;16(9-10):916-20. doi: 10.1016/s0264-410x(97)00298-3.
A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232-255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106-3113). Pretreatment of MA-104 cells with the VP4-peptide before infection with rotavirus prevented both the attachment of 35S-labelled virus and plaque formation in vitro. In vivo studies using a murine rotavirus model demonstrated that intragastric administration of VP4-peptide protected subjects from challenge with virulent rotavirus. These results clearly indicate the importance of this epitope in virus-cell interactions and their potential as a rotavirus vaccine candidate.
研究了一种与牛轮状病毒C486（BRV）VP4氨基酸序列232 - 255相对应的合成肽（VP4 - 肽），目的是确定Ijaz等人（《病毒学杂志》1991年，65卷，3106 - 3113页）先前报道的保护性免疫反应的起源。在用轮状病毒感染之前，用VP4 - 肽预处理MA - 104细胞可防止体外35S标记病毒的附着和噬斑形成。使用鼠轮状病毒模型的体内研究表明，胃内给予VP4 - 肽可保护实验对象免受强毒轮状病毒攻击。这些结果清楚地表明了该表位在病毒 - 细胞相互作用中的重要性及其作为轮状病毒疫苗候选物的潜力。
